C
C. Michael Stein
Researcher at Vanderbilt University Medical Center
Publications - 268
Citations - 20280
C. Michael Stein is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Population & Rheumatoid arthritis. The author has an hindex of 64, co-authored 251 publications receiving 18316 citations. Previous affiliations of C. Michael Stein include Veterans Health Administration & Columbia University.
Papers
More filters
Journal ArticleDOI
Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
TL;DR: Current users of typical and of atypical antipsychotic drugs had a similar, dose-related increased risk of sudden cardiac death.
Journal ArticleDOI
Premature coronary-artery atherosclerosis in systemic lupus erythematosus.
Yu Asanuma,Annette Oeser,Ayumi Shintani,Elizabeth Turner,Nancy J. Olsen,Sergio Fazio,MacRae F. Linton,Paolo Raggi,C. Michael Stein +8 more
TL;DR: In patients with systemic lupus erythematosus, the prevalence of coronary-artery Atherosclerosis is elevated and the age at onset is reduced, and early detection of atherosclerosis may provide an opportunity for therapeutic intervention.
Journal ArticleDOI
Azithromycin and the risk of cardiovascular death.
TL;DR: There was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease and patients in the highest decile of risk for cardiovascular disease.
Journal ArticleDOI
New drugs for rheumatoid arthritis.
Nancy J. Olsen,C. Michael Stein +1 more
TL;DR: Rheumatoid arthritis affects about 1 percent of the U.S. population and can cause irreversible joint deformities and functional impairment, although the cause of this autoimmune disease remains obscure.
Journal ArticleDOI
Genetic determinants of response to warfarin during initial anticoagulation.
Ute I. Schwarz,Marylyn D. Ritchie,Yuki Bradford,Chun Li,Scott M. Dudek,Amy Frye-Anderson,Richard B. Kim,Dan M. Roden,C. Michael Stein +8 more
TL;DR: Initial variability in the INR response to warfarin was more strongly associated with genetic variability inThe pharmacologic target of warfarIn, VKORC1, than with CYP2C9, and both of these genotypes had a significant influence on the required warfarins after the first 2 weeks of therapy.